Chalcogen Attached Directly To The Polycyclo Ring System By Nonionic Bonding Patents (Class 548/259)
  • Patent number: 10908333
    Abstract: Provided is an optical film 10 including a light-transmitting base material 11 and a light-transmitting functional layer 12 provided on one surface of the light-transmitting base material 11, wherein the optical film 10 has a spectral transmittance of less than 1% at a wavelength of 380 nm, a spectral transmittance of 10% or more and less than 60% at a wavelength of 410 nm, and a spectral transmittance of 70% or more at a wavelength of 440 nm, and wherein the light-transmitting functional layer 12 has a film thickness of 9 ?m or less.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 2, 2021
    Assignee: Dai Nippon Printing Co., Ltd.
    Inventors: Takahisa Nomura, Takanori Hamada, Masataka Nakashima, Kentaro Hata, Hiroshi Nakamura, Hiroki Nakagawa
  • Patent number: 10316024
    Abstract: Provided is an additive for imparting ultraviolet absorbency, or an additive for imparting a high refractive index, which has satisfactory compatibility with a resin serving as a matrix and can maintain high transparency even if added in high concentrations. Also provided is an additive with which the function of imparting both ultraviolet absorbency and a high refractive index can be realized by means of one kind of additive. This additive is represented by the following Formula (I): wherein at least one of R1a to R9a is a monovalent sulfur-containing group represented by the following Formula (i-1) or Formula (i-2): wherein R10a to R12a each represent a divalent hydrocarbon group or the like; and R13a represents a monovalent hydrocarbon group or the like.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: June 11, 2019
    Assignees: MIYOSHI OIL & FAT CO., LTD., TOKAI OPTICAL CO., LTD.
    Inventors: Koji Kawai, Kotaro Kaneko, Nobuhiro Kaneko, Yuichi Shishino, Kuniyoshi Okamoto
  • Patent number: 9682532
    Abstract: A laminate including a supporting member which is light transmissive; a supported substrate which is supported by the supporting member; an adhesive layer which is provided on a surface of the supported substrate on which surface the supported substrate is supported by the supporting member; and a release layer, which (i) is provided between the supporting member and the supported substrate and (ii) contains a polymer including, in a repeating unit, a structure having a light absorption property, a property of the polymer being changed when the polymer absorbs light irradiated via the supporting member.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: June 20, 2017
    Assignee: TOKYO OHKA KOGYO CO., LTD.
    Inventors: Atsushi Kubo, Hirofumi Imai, Koki Tamura, Takahiro Yoshioka, Yasushi Fujii, Yoshihiro Inao
  • Publication number: 20150126706
    Abstract: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.
    Type: Application
    Filed: January 7, 2015
    Publication date: May 7, 2015
    Inventors: GEERT-JAN BOONS, JUN GUO, XINGHAI NING, MARGARETHA WOLFERT
  • Patent number: 8975286
    Abstract: The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: March 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Vadim Y. Dudkin, Mark E. Fraley, Cheng Wang, Robert M. Garbaccio, Douglas C. Beshore, Scott K. Kuduk, Jason W. Skudlarek
  • Patent number: 8940859
    Abstract: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: January 27, 2015
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan Boons, Jun Guo, Xinghai Ning, Margaretha Wolfert
  • Publication number: 20140364603
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
  • Publication number: 20140309424
    Abstract: The invention describes novel direct synthesis methods for converting a precursor into a PET-tracer with a 18F-fluoromethoxy-group. The invention is also directed to novel and stable precursors for the direct radiosynthesis of protected derivatives of O—([18F]Fluoromethyl)tyrosines.
    Type: Application
    Filed: June 29, 2012
    Publication date: October 16, 2014
    Applicant: PIRAMAL IMAGING SA
    Inventors: Thomas Brumby, Keith Graham, Martin Kruger
  • Patent number: 8618110
    Abstract: The present invention includes and relates generally to compounds of structural Formula (I), or a salt, solvate, or prodrug thereof, which modulate apoptosis in cells. The present invention also provides pharmaceutical compositions containing these compounds, methods of making these compounds, and methods of using these compounds and pharmaceutical compositions for treatment of diseases associated with irregular apoptosis in cells.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: December 31, 2013
    Assignee: VM Discovery Inc.
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Publication number: 20130330366
    Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 12, 2013
    Inventors: Adam D. Hughes, Melissa Fleury
  • Publication number: 20130310570
    Abstract: Methods that include latent 1,3-dipole-functional compounds are disclosed herein. The latent 1,3-dipole-functional compound (e.g., an oxime) can be used to form an active 1,3-dipole-functional compound (e.g., a nitrile oxide) that can be used to react with a cyclic alkyne in a dipolar cycloaddition reaction.
    Type: Application
    Filed: September 27, 2011
    Publication date: November 21, 2013
    Applicant: UNIVERSITY OF GEORIGA RESEARCH FOUNDATION, INC.
    Inventors: Geert-Jan Boons, Frederic Friscourt, Petr A. Ledin, Ngalle Eric Mbua
  • Patent number: 8585938
    Abstract: UV absorbing compounds that are effective in blocking UV and short-wavelength blue light are disclosed. The UV absorbing compounds are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: November 19, 2013
    Assignee: Novartis AG
    Inventors: David L. Jinkerson, Walter R. Laredo
  • Publication number: 20130281347
    Abstract: Novel compounds based on diaminostilbene are provided. The compounds conform to the general structures The compounds are useful as optical brighteners. Compositions, such as laundry compositions, containing such compounds are also provided.
    Type: Application
    Filed: June 3, 2013
    Publication date: October 24, 2013
    Inventors: Robert L. Mahaffey, Eduardo Torres, Dominick J. Valenti, Patrick D. Moore, Leland G. Close
  • Patent number: 8541625
    Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: September 24, 2013
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Vladimir V. Popik, Andrei A. Poloukhtine, Geert-Jan Boons, Margaretha Wolfert
  • Publication number: 20130231488
    Abstract: The process for preparing 2-hydroxyphenyl alkenyl benzotriazole compounds and the process for preparing siloxane compounds containing 2-hydroxyphenyl benzotriazole function are disclosed.
    Type: Application
    Filed: October 25, 2010
    Publication date: September 5, 2013
    Applicant: L'Oreal
    Inventors: Herve Richard, Jinzhu Xu, Patricio Guerreiro, Yuan Wang, Jianping Guo
  • Patent number: 8519188
    Abstract: The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and especially to a racemic mixture. The present invention also relates to the use of these compounds as a medicament, and in particular for the treatment of cancer, and also to the compositions containing them.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: August 27, 2013
    Assignee: Marc-Henry Pitty
    Inventors: Denis Carniato, Karine Jaillardon, Olivier Busnel, Mathieu Gutmann, Jean-Francois Briand, Benoit Deprez, Dominique Thomas, Cécile Bougeret
  • Patent number: 8507469
    Abstract: The present invention relates to compounds of formula (I) wherein A is C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-hydroxyalkyl, C2-C6-alkenyl, C2-C6-halo-alkenyl, C3-C6-cycloalkyl, aryl-C1-C4-alkyl, aryl-C2-C4-alkenyl, aryl or hetaryl; is a single or double bond; X1 and X2 are N, CRx1, NRx2 or CRx3Rx4; Rx1, Rx3 and Rx4 are H, halogen, CN, NO2, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylcarbonyl, etc. or two geminal radicals Rx3 and Rx4 together with the carbon atom to which they are bound may form a carbonyl group or a 3- to 6-membered carbocyclic or heterocyclic spiro-annulated ring; Rx2 is hydrogen, C1-C6-alkyl, C1-C6-alkylcarbonyl, C1-C6-haloalkyl, etc.; or two vicinal radicals Rx1, Rx2, Rx3 or Rx4 together with X1 and X2 form a five- or six-membered carbocyclic or heterocyclic fused ring; Y1, Y2 and Y3 are N or CRy; Ry is H, halogen, CN, NO2, C1-C6-alkyl, C1-C6-alkoxy, C1-C6-alkylcarbonyl, C1-C6-haloalkyl, etc.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: August 13, 2013
    Assignee: Abbott GmbH & Co. KG
    Inventors: Thomas Schultz, Wilfried Braje, Sean Colm Turner, Andreas Haupt, Udo Lange, Karla Drescher, Karsten Wicke, Liliane Unger, Mario Mezler, Matthias Mayrer
  • Publication number: 20130164803
    Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.
    Type: Application
    Filed: August 6, 2012
    Publication date: June 27, 2013
    Applicant: University of George Research Foundation, Inc.
    Inventors: VLADIMIR V. POPIK, Andrei A. Poloukhtine, Geert-Jan Boons, Margaretha Wolfert
  • Patent number: 8465985
    Abstract: A fluorescent probe comprising a compound represented as (Fluorophore A)-S-(Fluorophore B) (Fluorophore A and Fluorophore B are fluorophores which emit fluorescence when they are irradiated with an excitation light of a wavelength of 600 to 950 nm, Fluorophore A has a property that it shows change of fluorescence characteristic before and after a specific reaction with an substance to be measured, and S represents a spacer which connects Fluorophore A and Fluorophore B), which compound shows substantial change in efficiency of fluorescence resonance energy transfer between Fluorophore A and Fluorophore B before and after the specific reaction with the objective substance, wherein Fluorophore A is represented by the following formula (AI): which uses and shows an excitation light wavelength/fluorescence wavelength in the near infrared region, lights of which region show superior biological tissue permeability, and enables measurement of an substance to be measured by the ratio method.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: June 18, 2013
    Assignee: The University of Tokyo
    Inventors: Tetsuo Nagano, Hirotatsu Kojima, Sakiko Aizawa, Kazuki Kiyose
  • Publication number: 20130144541
    Abstract: Novel cross-linking compounds that can be used in mass spectrometry, tandem mass spectrometry, and multi-stage tandem mass spectrometry to facilitate structural analysis of proteins and protein complexes are provided and have the formula: where X is an N-hydroxy-succinimidyl or similar heterocyclic group. Also provided is a method of mapping protein-protein interactions of protein complexes using various mass spectrometry techniques.
    Type: Application
    Filed: May 14, 2012
    Publication date: June 6, 2013
    Inventors: Scott Rychnovsky, Lan Huang
  • Patent number: 8415386
    Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein all of the variables are defined herein.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: April 9, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Pratik Devasthale, William N. Washburn, Wei Wang, Andres Hernandez, Saleem Ahmad, Guohua Zhao
  • Publication number: 20120329699
    Abstract: Novel compounds based on diaminostilbene are provided. The compounds conform to the general structures The compounds are useful as optical brighteners. Compositions, such as laundry compositions, containing such compounds are also provided.
    Type: Application
    Filed: September 4, 2012
    Publication date: December 27, 2012
    Applicant: MILLIKEN & COMPANY
    Inventors: Robert L. Mahaffey, Eduardo Torres, Dominick J. Valenti, Patrick D. Moore, Leland G. Close, JR.
  • Publication number: 20120322974
    Abstract: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.
    Type: Application
    Filed: March 13, 2012
    Publication date: December 20, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: GEERT-JAN BOONS, Jun Guo, Xinghai Ning, Margaretha Wolfert
  • Publication number: 20120295318
    Abstract: Cyclic alkynes (e.g., cyclooctynes such as dibenzocyclooctynes) can be photochemically generated from cyclopropenones as disclosed herein. The cyclic alkynes can be reacted (e.g., in situ) with materials having alkyne-reactive groups (e.g., azide groups in a “click” reaction). In preferred embodiments, the generation and reaction of the cyclic alkyne can proceed in the absence of a catalyst (e.g., Cu(I)). These reactions can be useful, for example, for the selective labeling of living cells that are metabolically modified with azido-containing surface monosaccharides, or for light-directed surface patterning.
    Type: Application
    Filed: August 6, 2012
    Publication date: November 22, 2012
    Applicant: University of George Research Foundation, Inc.
    Inventors: VLADIMIR V. POPIK, Andrei A. Poloukhtine, Geert-Jan Boons, Margaretha Wolfert
  • Patent number: 8308198
    Abstract: The present invention relates to a water-based fluorescent ink for the purpose of measurement or judgment of the fluorescence emission in a visible light region by an excitation wavelength in a predetermined ultraviolet range, containing water, a coloring material dissolved or dispersed in water, and an organic solvent, having a plurality of fluorescent groups in the coloring material structure of the coloring material, and using a water-soluble coloring material having a sulfonic acid group as the water-soluble group in the state of a free acid, capable of improving the water resistance and the light resistance, dramatically increasing the content of the fluorescent coloring material in the ink, which has conventionally been included only by a small amount in the ink due to the concentration quenching problem, obtaining preferable fluorescence emission and water resistance of the recorded image, and providing preferable adhesion resistance to the recording medium of the coloring material and reliability.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: November 13, 2012
    Assignee: Canon Kabushiki Kaisha
    Inventors: Masako Udagawa, Shoji Koike, Makoto Aoki, Akira Nagashima, Shinichi Hakamada
  • Patent number: 8288557
    Abstract: Bivalent linkers derived from compounds of formulae (V), (VI), and (VII), where X1 and X2 are leaving groups and the other variables are as defined in the claims, to be included in or for preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates are described.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: October 16, 2012
    Assignee: Endocyte, Inc.
    Inventors: Iontcho Radoslavov Vlahov, Christopher Paul Leamon, Apparao Satyam, Stephen J. Howard
  • Patent number: 8273877
    Abstract: Substituted tetraazapentalenes have two benzenoid rings and eight substitutable positions. Substitutions are made of hydrogen or C—H groups in favor of amino groups, nitro groups or nitrogen atoms. The tetraazapentalenes are synthesized through an intermediate azo, which is made from a 1:1:1 molar ratio of a nitroaniline, sodium nitrite and an amine.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: September 25, 2012
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Alfred G. Stern, Patrick A. Caruana
  • Patent number: 8262948
    Abstract: Disclosed are ophthalmic device materials having improved light transmission characteristics. The materials contain a combination of certain UV absorbers and blue-light absorbing chromophores.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventors: Walter R. Laredo, Ali E. Akinay
  • Patent number: 8262947
    Abstract: Benzotriazole UV/Visible light-absorbing monomers are disclosed. The UV/Vis absorbers are particularly suitable for use in intraocular lens materials.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: September 11, 2012
    Assignee: Novartis AG
    Inventor: Walter R. Laredo
  • Patent number: 8262949
    Abstract: The instant invention relates to novel benzotriazole UV-absorbers having a long wavelength shifted absorption spectrum with significant absorbance up to 410-420 nm. Further aspects of the invention are a process for their preparation, a UV stabilized composition containing the new UV-absorbers and the use of the new compounds as UV-light stabilizers for organic materials.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: September 11, 2012
    Assignee: BASF SE
    Inventors: Katharina Fritzsche, Markus Grob, Adalbert Braig, Ilona Marion Kienzle, Gérard Daniel Georges Vilain
  • Publication number: 20120213806
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: February 16, 2012
    Publication date: August 23, 2012
    Applicant: THERAVANCE, INC.
    Inventors: Melissa Fleury, Roland Gendron, Adam D. Hughes
  • Publication number: 20120184683
    Abstract: Compounds linked to a solid support through a divalent linker moiety are disclosed. In particular, compounds such as 1-hydroxybenzotriazole-6-carboxylic acid are directly linked to the support under mild conditions (i.e., in aqueous or organic solvents at neutral pH and at room temperature). The polymer bound 1-hydroxybenzotriazole-6-carboxylic acid can be used for the derivatization of amines as well as for single step amino group modification of proteins, peptides, and amines via acylation or sulfonylation reactions. A flow through device and method for the single step amino group modifications of proteins, peptides, and amines is disclosed. Also disclosed is a flow through device for the detection of amines in a sample. Additionally, a device and method for the detection of amines in a sample using 1-hydroxybenzotriazole-6-carboxylic acid are disclosed. In a preferred embodiment, the device is used to detect the presence of amines in a spoiled meat product.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 19, 2012
    Applicant: The University of Maryland, Baltimore County
    Inventor: Aristotle G. KALIVRETENOS
  • Publication number: 20120172575
    Abstract: 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.
    Type: Application
    Filed: March 13, 2012
    Publication date: July 5, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: GEERT-JAN BOONS, Jun Guo, Xinghai Ning, Margaretha Wolfert
  • Publication number: 20120149741
    Abstract: There are provided compounds of Formula (I) wherein three of A1, A2, A3, and A4 represent CH and one of A1, A2, A3, and A4 represents CR1; R1 represents SO2R2 or NHCOR2 wherein R2 represents C1-C6 alkyl optionally substituted by one or more halogen, hydroxyl or alkoxy groups; R9 represents C6-C10 aryl; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 14, 2008
    Publication date: June 14, 2012
    Applicants: Biomarin IGA Limited, Summit Corporation PLC
    Inventor: Graham Michael WYNNE
  • Publication number: 20120135977
    Abstract: The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Application
    Filed: September 28, 2011
    Publication date: May 31, 2012
    Inventors: Douglas C. Beshore, Vadim Dudkin, Robert M. Garbaccio, Adam W. Johnson, Scott D. Kuduk, Jason W. Skudlarek, Cheng Wang, Mark E. Fraley
  • Publication number: 20110287999
    Abstract: Novel compounds based on diaminostilbene are provided. The compounds conform to the general structures The compounds are useful as optical brighteners. Compositions, such as laundry compositions, containing such compounds are also provided.
    Type: Application
    Filed: May 18, 2011
    Publication date: November 24, 2011
    Inventors: Robert L. Mahaffey, Eduardo Torres, Dominick J. Valenti, Patrick D. Moore, Leland G. Close, JR.
  • Publication number: 20110195934
    Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable faints thereof according to wherein all of the variables are defined herein.
    Type: Application
    Filed: October 8, 2009
    Publication date: August 11, 2011
    Inventors: Pratik Devasthale, Wliiam N. Washburn, Wei Wang, Andres Hernandez, Saleem Ahmad, Guohua Zhao
  • Publication number: 20110177617
    Abstract: The invention describes the use of particular cross-linking reagents containing 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole groups as reactive groups for cross-linking reactions of supramolecular target-ligand-complexes. The resulting cross-linked products may be directly analyzed using mass spectrometry, gel or fluorescence based technologies, X-ray crystallography, NMR or other analytical technologies. The method using High-Mass MALDI mass spectrometry provides various biological applications such as characterization of antibodies, drug discovery, and protein complex analysis including automated or higher throughput applications.
    Type: Application
    Filed: May 27, 2010
    Publication date: July 21, 2011
    Inventors: Claudia Bich, Alexis Nazabal, Ryan Wenzel, Renato Zenobi
  • Publication number: 20110166138
    Abstract: Disclosed are compounds and compositions that inhibit the action of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL), methods of inhibiting FAAH and MGL, methods of modulating cannabinoid receptors, and methods of treating various disorders related to modulation of cannabinoid receptors.
    Type: Application
    Filed: March 17, 2009
    Publication date: July 7, 2011
    Inventors: Alexandros Makriyannis, Lakshmipathi Pandarinathan, Nikolai Zvonok, Teija Parkkari, Lauren Chapman
  • Patent number: 7939330
    Abstract: A fluorescent probe which specifically and efficiently traps nitrogen monoxide, zinc ion etc. to emit fluorescence is provided. A compound represented by the following general formula (I): [wherein R1 and R2 represent hydrogen atom, or a group represented by the following formula (A): (wherein X1 to X4 represent hydrogen atom, an alkyl group, or a protective group for amino group, and m and n represent 0 or 1); R3 and R4 represent hydrogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R5 to R12 represent hydrogen atom, sulfo group, phospho group, a halogen atom, or a C1-6 alkyl group; R13 and R14 represent a C1-18 alkyl group; Z1 represents oxygen atom, sulfur atom, or —N(R15)— (wherein R15 represents hydrogen atom, or a C1-6 alkyl group); Y1 and Y2 represent —C(?O)—, —C(?S)—, or —C(R16)(R17) (wherein R16 and R17 represent a C1-6 alkyl group); and M? represents a counter ion in a number required for neutralizing the charge].
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: May 10, 2011
    Inventors: Tetsuo Nagano, Eita Sasaki, Hirotatsu Kojima, Tomoya Hirano, Kazuya Kikuchi
  • Publication number: 20110104162
    Abstract: The present invention relates to a compound of general formula (I): and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and especially to a racemic mixture. The present invention also relates to the use of these compounds as a medicament, and in particular for the treatment of cancer, and also to the compositions containing them.
    Type: Application
    Filed: June 15, 2009
    Publication date: May 5, 2011
    Applicant: Cytomics Systems
    Inventors: Denis Carniato, Karine Jaillardon, Olivier Busnel, Mathieu Gutmann, Jean-Francois Briand, Benoit Deprez, Dominique Thomas, Cécile Bougeret
  • Patent number: 7923568
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: April 12, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark L. Greenlee, Dongfang Meng, Dann L. Parker, Jr., Wanying Sun, Kenneth J. Wildonger, Robert R. Wilkening
  • Patent number: 7825257
    Abstract: The synthesis of benzotriazole monomers and the use of the benzotriazole monomers and one or more other monomers to prepare ultraviolet (UV) light absorbing polymer compositions. The synthetic methods described in this application provide a significant improvement over the previous methods used to prepare benzotriazole monomers.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: November 2, 2010
    Assignee: Bausch & Lomb Incorporated
    Inventors: Keshav Deo, Chandrakant Chunilal Shah, Kalpesh Patel, Nilpesh Patel, Viral Parekh, Ronak Patel, Jignesh Soni, Hiral Shah, David E. Seelye, Mahendra P. Nandu
  • Publication number: 20100267671
    Abstract: The present invention includes and relates generally to compounds which modulate apoptosis in cells. The present invention also provides pharmaceutical compositions containing these compounds, methods of making these compounds, and methods of using these compounds and pharmaceutical compositions for treatment of diseases associated with irregular apoptosis in cells.
    Type: Application
    Filed: February 9, 2010
    Publication date: October 21, 2010
    Inventors: Jay Jie-Qiang Wu, Ling Wang
  • Patent number: 7803359
    Abstract: UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: September 28, 2010
    Assignee: Alcon, Inc.
    Inventors: David L. Jinkerson, Joseph I. Weinschenk, III, W. Dennis Dean
  • Publication number: 20100240715
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.
    Type: Application
    Filed: May 19, 2010
    Publication date: September 23, 2010
    Inventors: Milan Bruncko, Hong Ding, Steven Elmore, Aaron Kunzer, Christopher L. Lynch, William McClellan, Cheol-Min Park, Andrew Petros, Xiaohong Song, Xilu Wang, Noah Tu, Michael Wendt
  • Publication number: 20100204280
    Abstract: A compound of Formula, (I) or Formula: (II)
    Type: Application
    Filed: May 29, 2008
    Publication date: August 12, 2010
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Christophe Pardin, Jeffrey W. Keillor, William D. Lubell
  • Publication number: 20100197806
    Abstract: The invention provides a method comprising the steps of (i) reacting a water-soluble and non-peptidic polymer having two or more terminal hydroxyl groups with di(1-benzotriazolyl)carbonate to form a water-soluble and non-peptidic polymer having two or more 1-benzotriazolylcarbonate ester groups; and (ii) reacting the water-soluble and non-peptidic polymer having two or more 1-benzotriazolylcarbonate ester groups with a water-soluble and non-peptidic polymer having three or more primary amino groups under conditions effective to form a cross-linked polymer composition.
    Type: Application
    Filed: April 8, 2010
    Publication date: August 5, 2010
    Applicant: Nektar Therapeutics
    Inventor: Antoni Kozlowski
  • Patent number: 7750028
    Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula its use and pharmaceutical preparations comprising this crystal modifications.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: July 6, 2010
    Assignee: Novartis AG
    Inventors: Robert Portmann, Urs C Hofmeier, Andreas Burkhard, Walter Scherrer, Martin Szelagiewicz
  • Publication number: 20100168188
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.
    Type: Application
    Filed: September 29, 2006
    Publication date: July 1, 2010
    Inventors: Mark L. Greenlee, Dongfang Meng, Dann L. Parker, JR., Wanying Sun, Kenneth J. Wildonger, Robert R. Wilkening